TY - JOUR
T1 - Factors associated with fears due to COVID-19
T2 - A scleroderma patient-centered intervention network (SPIN) COVID-19 cohort study
AU - for the SPIN Patient Advisors
AU - SPIN Investigators
AU - Wu, Yin
AU - Kwakkenbos, Linda
AU - Henry, Richard S.
AU - Carrier, Marie Eve
AU - Gagarine, Maria
AU - Harb, Sami
AU - Bourgeault, Angelica
AU - Tao, Lydia
AU - Carboni-Jiménez, Andrea
AU - Negeri, Zelalem
AU - Patten, Scott
AU - Bartlett, Susan J.
AU - Mouthon, Luc
AU - Varga, John
AU - Benedetti, Andrea
AU - Thombs, Brett D.
AU - Fortuné, Catherine
AU - Gietzen, Amy
AU - Guillot, Geneviève
AU - Lewis, Nancy
AU - Richard, Michelle
AU - Sauvé, Maureen
AU - Welling, Joep
AU - Fligelstone, Kim
AU - Gottesman, Karen
AU - Leite, Catarina
AU - Pérez, Elisabet
AU - Baron, Murray
AU - Malcarne, Vanessa
AU - Mayes, Maureen D.
AU - Nielson, Warren R.
AU - Riggs, Robert
AU - Assassi, Shervin
AU - Ells, Carolyn
AU - van den Ende, Cornelia
AU - Frech, Tracy
AU - Harel, Daphna
AU - Hinchcliff, Monique
AU - Hudson, Marie
AU - Johnson, Sindhu R.
AU - Larche, Maggie
AU - Nguyen, Christelle
AU - Pope, Janet
AU - Rannou, François
AU - Reyna, Tatiana Sofia Rodriguez
AU - Schouffoer, Anne A.
AU - Suarez-Almazor, Maria E.
AU - Agard, Christian
AU - Albert, Alexandra
AU - Bernstein, Elana J.
N1 - Funding Information:
The SPIN COVID-19 Cohort was funded by the Canadian Institutes of Health Research (VR4-172745), the McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund; Scleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; Scleroderma Association of BC; and Sclérodermie Québec. The Scleroderma Patient-centered Intervention Network (SPIN) has received funding for its core activities, including the SPIN Cohort, from the Canadian Institutes of Health Research; the Arthritis Society; the Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, Canada; the Jewish General Hospital Foundation, Montreal, Canada; McGill University, Montreal, Canada; the Scleroderma Society of Ontario; Scleroderma Canada; Sclérodermie Québec; Scleroderma Manitoba; Scleroderma Atlantic; the Scleroderma Association of BC; Scleroderma SASK; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; and Scleroderma Queensland. Dr. Wu was supported by a Fonds de recherche du Québec - Santé (FRQ-S) postdoctoral fellowship award, Dr. Henry by a Mitacs postdoctoral fellowship award, Mr. Harb and Ms. Carboni-Jiménez by a CIHR Canada Graduate Scholarship – Master's award, Dr. Benedetti by a FRQ-S researcher salary award, and Dr. Thombs by a Tier 1 Canada Research Chair.
Funding Information:
The SPIN COVID-19 Cohort was funded by the Canadian Institutes of Health Research ( VR4-172745 ), the McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund; Scleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; Scleroderma Association of BC; and Sclérodermie Québec. The Scleroderma Patient-centered Intervention Network (SPIN) has received funding for its core activities, including the SPIN Cohort, from the Canadian Institutes of Health Research; the Arthritis Society; the Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, Canada; the Jewish General Hospital Foundation, Montreal, Canada; McGill University, Montreal, Canada; the Scleroderma Society of Ontario; Scleroderma Canada; Sclérodermie Québec; Scleroderma Manitoba; Scleroderma Atlantic; the Scleroderma Association of BC; Scleroderma SASK; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; and Scleroderma Queensland. Dr. Wu was supported by a Fonds de recherche du Québec - Santé (FRQ-S) postdoctoral fellowship award, Dr. Henry by a Mitacs postdoctoral fellowship award, Mr. Harb and Ms. Carboni-Jiménez by a CIHR Canada Graduate Scholarship – Master's award, Dr. Benedetti by a FRQ-S researcher salary award, and Dr. Thombs by a Tier 1 Canada Research Chair.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Introduction: No studies have examined factors associated with fear in any group of people vulnerable during COVID-19 due to pre-existing medical conditions. Objective: To investigate factors associated with fear of consequences of COVID-19 among people living with a pre-existing medical condition, the autoimmune disease systemic sclerosis (SSc; scleroderma), including country. Methods: Pre-COVID-19 data from the Scleroderma Patient-centered Intervention Network (SPIN) Cohort were linked to COVID-19 data collected in April 2020. Multivariable linear regression was used to assess factors associated with continuous scores of the 10-item COVID-19 Fears Questionnaire for Chronic Medical Conditions, controlling for pre-COVID-19 anxiety symptoms. Results: Compared to France (N = 156), COVID-19 Fear scores among participants from the United Kingdom (N = 50) were 0.12 SD (95% CI 0.03 to 0.21) higher; scores for Canada (N = 97) and the United States (N = 128) were higher, but not statistically significant. Greater interference of breathing problems was associated with higher fears due to COVID-19 (Standardized regression coefficient = 0.12, 95% CI 0.01 to 0.23). Participants with higher financial resources adequacy scores had lower COVID-19 Fear scores (Standardized coefficient = −0.18, 95% CI −0.28 to −0.09). Conclusions: Fears due to COVID-19 were associated with clinical and functional vulnerabilities in this chronically ill population. This suggests that interventions may benefit from addressing specific clinical issues that apply to specific populations. Financial resources, health policies and political influences may also be important. The needs of people living with chronic illness during a pandemic may differ depending on the social and political context in which they live.
AB - Introduction: No studies have examined factors associated with fear in any group of people vulnerable during COVID-19 due to pre-existing medical conditions. Objective: To investigate factors associated with fear of consequences of COVID-19 among people living with a pre-existing medical condition, the autoimmune disease systemic sclerosis (SSc; scleroderma), including country. Methods: Pre-COVID-19 data from the Scleroderma Patient-centered Intervention Network (SPIN) Cohort were linked to COVID-19 data collected in April 2020. Multivariable linear regression was used to assess factors associated with continuous scores of the 10-item COVID-19 Fears Questionnaire for Chronic Medical Conditions, controlling for pre-COVID-19 anxiety symptoms. Results: Compared to France (N = 156), COVID-19 Fear scores among participants from the United Kingdom (N = 50) were 0.12 SD (95% CI 0.03 to 0.21) higher; scores for Canada (N = 97) and the United States (N = 128) were higher, but not statistically significant. Greater interference of breathing problems was associated with higher fears due to COVID-19 (Standardized regression coefficient = 0.12, 95% CI 0.01 to 0.23). Participants with higher financial resources adequacy scores had lower COVID-19 Fear scores (Standardized coefficient = −0.18, 95% CI −0.28 to −0.09). Conclusions: Fears due to COVID-19 were associated with clinical and functional vulnerabilities in this chronically ill population. This suggests that interventions may benefit from addressing specific clinical issues that apply to specific populations. Financial resources, health policies and political influences may also be important. The needs of people living with chronic illness during a pandemic may differ depending on the social and political context in which they live.
KW - Anxiety
KW - COVID-19
KW - Chronic medical condition
KW - Fear
KW - Mental health
KW - Scleroderma
KW - Systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85097180260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097180260&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychores.2020.110314
DO - 10.1016/j.jpsychores.2020.110314
M3 - Article
C2 - 33271402
AN - SCOPUS:85097180260
SN - 0022-3999
VL - 140
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
M1 - 110314
ER -